How has been the historical performance of Mankind Pharma?

Aug 13 2025 11:22 PM IST
share
Share Via
Mankind Pharma has shown consistent growth over the past five years, with net sales increasing from INR 6,214.43 crore in March 2021 to INR 12,207.44 crore in March 2025, alongside significant rises in profits and total assets. The company’s operating profit rose from INR 1,819.05 crore to INR 3,554.72 crore, reflecting strong financial performance.
Answer:
The historical performance of Mankind Pharma shows a consistent growth trajectory in net sales and profits over the past five years.

Breakdown:
Mankind Pharma's net sales have increased significantly from INR 6,214.43 crore in March 2021 to INR 12,207.44 crore in March 2025. This upward trend is mirrored in total operating income, which rose from INR 6,214.43 crore to INR 12,207.44 crore during the same period. The company's total expenditure, excluding depreciation, also grew, reaching INR 9,189.51 crore in March 2025, up from INR 4,566.33 crore in March 2021. Operating profit (PBDIT) has shown a positive trend, climbing from INR 1,819.05 crore in March 2021 to INR 3,554.72 crore in March 2025. Profit before tax increased from INR 1,679.93 crore to INR 2,504.09 crore, while profit after tax rose from INR 1,281.35 crore to INR 1,994.35 crore over the same period. The company's total assets surged from INR 6,323.62 crore in March 2021 to INR 27,651.64 crore in March 2025, indicating strong growth in both current and non-current assets. Total liabilities also increased significantly, from INR 6,323.62 crore to INR 27,651.64 crore, primarily due to a rise in long-term borrowings from INR 57.67 crore to INR 5,526.19 crore. Cash flow from operating activities improved from INR 1,137 crore in March 2021 to INR 2,413 crore in March 2025, while cash flow from investing activities showed a substantial outflow of INR 12,624 crore in March 2025. Overall, Mankind Pharma has demonstrated robust growth in revenue and profitability, alongside a significant increase in assets and liabilities.
{{stockdata.stock.stock_name.value}} Live

{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)

{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)


Our weekly and monthly stock recommendations are here
Loading...
{{!sm.blur ? sm.comp_name : ''}}
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Entry Price
Target Price
{{sm.target_price }} ({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News